Kiora Pharmaceuticals, Inc.
Recent News
-
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa
Encinitas, California--(Newsfile Corp. - November 9, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its third quarter 2023 financial results and is providing an update on its plans to advance clinical development of KIO-301 for other inherited retinal diseases. On November 4, 2023, Kiora reported results from the ABACUS-1 study, a Phase 1b first-in-human clinical trial of the Company's molecular photoswitch, KIO-301, in patients with late-stage retinitis pigmentosa (RP). The key findings from ABACUS-1 demonstrated...
2023-11-09 7:18 AM EST -
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa
Topline Phase I/II First-in-Human Results Presented at AAO 2023Significant improvement in visual field, in concordance with trended improvements in visual acuity and functional visionFunctional MRI demonstrates increased brain activity in visual cortexNovel small molecule photoswitch is safe and tolerableCompany presentation available on IR website (ir.kiorapharma.com)Encinitas, California--(Newsfile Corp. - November 4, 2023) - Kiora Pharmaceuticals (NASDAQ
2023-11-04 12:15 PM EDT -
Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference
Encinitas, California--(Newsfile Corp. - October 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation from the Lytham Partners Fall 2023 Investor Conference taking place on Tuesday October 17, 2023. As part of the presentation, Melisa Tosca, CPA, Kiora's Executive Vice President of Finance, will provide an overview of the Company's business and clinical development pipeline for inherited retinal diseases. The presentation is accessible on-demand starting at 7:00 am on the day of the...
2023-10-16 7:00 AM EDT -
Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa
Encinitas, California--(Newsfile Corp. - October 3, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) has received Investigational New Drug Application approval in Australia to enroll up to six additional patients in the ABACUS study of KIO-301. ABACUS was initially designed to evaluate patients with Retinitis Pigmentosa (RP). Based on encouraging findings previously shared, Kiora sought this approval to evaluate additional patients with late-stage RP as well as those with late-stage Choroideremia (CHM), a rare form of hereditary retinal degeneration. Plans remain for...
2023-10-03 7:00 AM EDT -
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
Encinitas, California--(Newsfile Corp. - September 21, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced that its board of directors has appointed Praveen Tyle, PhD, who currently serves as a director, as its new Chairman. Dr. Tyle succeeds current Chairman Paul Chaney who is retiring after serving 17 years on the board."We look forward to Dr. Tyle's leadership as Chairman, where he'll continue to bring valuable industry experience in guiding our development of new treatments for eye disease," said Brian M....
2023-09-21 7:00 AM EDT -
Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
Encinitas, California--(Newsfile Corp. - September 18, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the completion of the final patient's last endpoint evaluation from the ABACUS study of KIO-301. KIO-301 is A molecular photoswitch being evaluated in a Phase 1B clinical trial for vision restoration in late-stage Retinitis Pigmentosa (RP). Topline study results will be reported November 4 at the upcoming American Academy of Ophthalmology annual meeting. ABACUS enrolled six patients and evaluated 12 eyes at three doses....
2023-09-18 7:00 AM EDT -
Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
Encinitas, California--(Newsfile Corp. - September 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from the ABACUS study of KIO-301 in patients with late-stage retinitis pigmentosa will be presented at the American Academy of Ophthalmology (AAO 2023) conference on November 4, 2023. The late-breaking abstract has been accepted for presentation at the retinal subspecialty day and will include findings from all six participants and 12 evaluated eyes in the Phase 1b, dose-escalating, open-label study....
2023-09-14 7:01 AM EDT -
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
Encinitas, California--(Newsfile Corp. - September 1, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that the Company's Special Meeting of Stockholders (the "Special Meeting") held on August 31, 2023 at 9:00 a.m. Pacific Time was convened and adjourned, without any business being conducted, due to lack of the required quorum.A quorum consists of one third of the voting power of the outstanding shares of the Company entitled to vote generally in the election of directors. There...
2023-09-01 7:00 AM EDT -
Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases
Encinitas, California--(Newsfile Corp. - August 29, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites you to participate in a webinar highlighting the progress of molecular photoswitches in retinitis pigmentosa and the future development plans in additional inherited retinal diseases such as choroideremia. The webinar is being hosted by the Choroideremia Research Foundation (CRF) and will include presentations from and discussions with retinal disease expert Christine Kay, M.D., Vitreoretinal Surgeon and IRD specialist at Vitreoretinal Associates, and Eric Daniels, M.D., Chief Development Officer...
2023-08-29 1:43 PM EDT -
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
Encinitas, California--(Newsfile Corp. - August 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has been granted U.S. (Patent # 11,730,716) and European Patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules. This intellectual property (IP) further protects Kiora's pipeline by covering multiple small molecule analogs, delivery methods, and several inflammatory-related therapeutic applications, including posterior non-infectious uveitis, thereby extending market exclusivity for approved indications in the U.S. and Europe.With...
2023-08-23 7:00 AM EDT
